Issue 5/2010

Selenium as a chemoprotective anti-cancer agent: Reality or wishful thinking? (383 — 391)

L. NOVOTNY, P. RAUKO, S. B. KOMBIAN, I. O. EDAFIOGHO

DOI: 10.4149/neo_2010_05_383

Immunophenotype characterization of hematopoietic stem cells, progenitor cells restricted to myeloid lineage and their leukemia counterparts (392 — 400)

M. FAJTOVA, O. BABUSIKOVA

DOI: 10.4149/neo_2010_05_392

PARP-1 inhibitors: a novel genetically specific agents for cancer therapy (401 — 405)

L. CIPAK, S. JANTOVA

DOI: 10.4149/neo_2010_05_401

Binding of AR to SMRT/N-CoR complex and its co-operation with PSA promoter in prostate cancer cells treated with natural histone deacetylase inhibitor NaB (406 — 414)

K. TRTKOVA, L. PASKOVA, N. MATIJESCUKOVA, M. STRNAD, Z. KOLAR

DOI: 10.4149/neo_2010_05_406

Polymorphisms in metabolizing enzymes and the risk of head and neck squamous cell carcinoma in the Slavic population of the central Europe (415 — 421)

P. SOUCEK, S. SUSOVA, B. MOHELNIKOVA-DUCHONOVA, J. GROMADZINSKA, A. MORAVIEC-SZTANDERA, P. VODICKA, L. VODICKOVA

DOI: 10.4149/neo_2010_05_415

The effect of probiotic microorganisms and bioactive compounds on chemically induced carcinogenesis in rats (422 — 428)

I. BERTKOVA, E. HIJOVA, A. CHMELAROVA, G. MOJZISOVA, D. PETRASOVA, L. STROJNY, A. BOMBA, R. ZITNAN

DOI: 10.4149/neo_2010_05_422

Possible prognostic value of nucleolar morphology in pathologic cells of B-chronic lymphocytic leukemia (429 — 437)

M. KLOBUSICKA, J. KUSENDA, L. STEVULOVA, A. KOVARIKOVA, O. BABUSIKOVA

DOI: 10.4149/neo_2010_05_429

Neutrophilic differentiation modulates the apoptotic response of HL-60 cells to sodium butyrate and sodium valproate (438 — 448)

J. VRBA, P. DOLEZEL, J. ULRICHOVA

DOI: 10.4149/neo_2010_05_438

Distinguishing of primary mediastinal B-cell lymphoma and diffuse large B-cell lymphoma using real-time quantitative polymerase chain reaction (449 — 454)

H. VOTAVOVA, K. FORSTEROVA, V. CAMPR, J. SRITESKY, Z. VELENSKA, R. PYTLIK, K. KUBACKOVA, B. PROCHAZKA, R. KODET, I. SPICKA, H. KREJCOVA, M. TRNENY, P. KLENER

DOI: 10.4149/neo_2010_05_449

Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies (455 — 464)

D. OCADLIKOVA, F. KRYUKOV, K. MOLLOVA, L. KOVAROVA, I. BURESOVA, E. MATEJKOVA, M. PENKA, T. BUCHLER, R. HAJEK, J. MICHALEK

DOI: 10.4149/neo_2010_05_455

Promoter methylation and expression changes of CDH1 and P16 genes in invasive breast cancer and adjacent normal breast tissue (465 — 472)

A. CELEBILER_CAVUSOGLU, A. I. SEVINC, S. SAYDAM, T. CANDA, Z. BASKAN, Y. KILIC, M. SAKIZLI

DOI: 10.4149/neo_2010_05_465

Synthetic isothiocyanate indole-3-ethyl isothiocyanate (homoITC) enhances sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to cisplatin (473 — 481)

P. STEHLIK, H. PAULIKOVA, L. HUNAKOVA

DOI: 10.4149/neo_2010_05_473

Expression of RAN, ZHX-2, and CHC1L genes in multiple myeloma patients and in myeloma cell lines treated with HDAC and Dnmts inhibitors (482 — 487)

S. LEGARTOVA, A. HARNICAROVA-HORAKOVA, E. BARTOVA, R. HAJEK, L. POUR, S. KOZUBEK

DOI: 10.4149/neo_2010_05_482

Detecting soluble Clusterin in in-vitro and in-vivo models of prostate cancer (488 — 493)

F. P. GIRARD, J. BYRNE, M. DOWNES, D. FANNING, F. DESGRANDCHAMPS, J. M. FITZPATRICK, R. W. WATSON

DOI: 10.4149/neo_2010_05_488